This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Their passion and curiosity to expand the boundaries of toxicology research illuminated the room. As experts in early-phase drug development , from discovery through Phase II clinicalresearch , we at Altasciences can share with STC members our accumulated knowledge and experience, and provide mentorship for future toxicologists.
In addition, their collective research insights will greatly enhance existing efforts to translate the scientific potential of our AIM technology into therapies designed to address significant unmet patient needs.”.
Beyond the sheer breadth of patients involved, the project encompasses leading scientists from seven UK universities (Cambridge, Cardiff, Edinburgh, Imperial College London, Newcastle, University College London, and Swansea), non-profit associations, and various companies within the clinicalresearch industry.
Additional expanded clinicalresearch services at the Houston facility include: Expanded blood processing rooms Dedicated dark rooms for multiplex IHC staining, imaging, and flow cytometry Histotechnology capabilities Digital Pathology with artificial intelligence (AI) Dedicated clean rooms for genomics.
in CellBiology from Utrecht University. Earlier in his career, he held development and engineering positions at BAC, part of Life Technologies, Unilever, and Crucell. Dr. van de Laar holds a M.Sc. in Bioprocess Technology from Wageningen University and a Ph.D. About AM-Pharma.
We organize all of the trending information in your field so you don't have to. Join 15,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content